{"id":"NCT03857542","sponsor":"Allergan","briefTitle":"A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia","officialTitle":"A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Participants With Presbyopia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-01","primaryCompletion":"2020-09-10","completion":"2020-09-10","firstPosted":"2019-02-28","resultsPosted":"2021-12-29","lastUpdate":"2021-12-29"},"enrollment":427,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Presbyopia"],"interventions":[{"type":"DRUG","name":"Pilocarpine HCl Ophthalmic Solution","otherNames":["AGN-190584","VUITY"]},{"type":"OTHER","name":"Vehicle","otherNames":[]}],"arms":[{"label":"Vehicle","type":"PLACEBO_COMPARATOR"},{"label":"Pilocarpine HCl Ophthalmic Solution","type":"EXPERIMENTAL"}],"summary":"This clinical study will evaluate pilocarpine hydrogen chloride (HCl) ophthalmic solution (AGN-190584) in an expanded participant population to establish efficacy, safety, and tolerability versus the vehicle-control when administered, over a 30-day study intervention period, once daily bilaterally in participants with presbyopia.","primaryOutcome":{"measure":"Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular DCNVA, Without Losing More Than 5 Letters of Mesopic, High-Contrast, Binocular CDVA With the Same Refractive Correction at Day 30, Hour 3","timeFrame":"Baseline (Day 1) to Day 30 (Hour 3)","effectByArm":[{"arm":"Vehicle","deltaMin":10.8,"sd":null},{"arm":"Pilocarpine HCl Ophthalmic Solution","deltaMin":26,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":35,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":215},"commonTop":["Headache","Conjunctival hyperaemia","Eye pain","Vision blurred"]}}